Hollings Home  
 
David M Neskey, MD
Assistant Professor of Otolaryngology
College of Medicine
MUSC

Email: neskey@musc.edu
 
       Print This Page
       
 
 


 

David M Neskey, MD

Return to Search Page  

Research Interest:

In addition to exploring my research interests in the molecular mechanisms of tumor progression and metastasis in head and neck squamous cell carcinomas, I am a head and neck cancer surgeon devoted to providing the highest level of care to patients with head and neck cancer. These dual privileges and responsibilities allow me to care for a unique patient population with a life-threatening disease and simultaneously utilize knowledge gleaned from the laboratory to directly impact my patients’ outcomes. I leverage the high volume of head and neck cancer patients seen at Hollings Cancer Center to continue patient accrual for the prospective tissue banking protocol and other proposed experiments. This patient population has the potential to benefit from the knowledge gained from the proposed experiments in the future. Additionally, I am an active participate in the clinical and surgical training of our fellows and residents.

Selected Publications:

1.Neskey DM, Klein JD, Hicks S, Garden AS, Bell DM, El-Naggar AK, Kies MS, Weber RS, Kupferman ME. Prognostic factors associated with decreased survival in patients with acinic cell carcinoma. JAMA Otolaryngol Head Neck Surg. .139(11):1195-202, 2013.
View in: PubMed

2.Gadhikar MA, Sciuto MR, Alves MV, Pickering CR, Osman AA, Neskey DM, Zhao M, Fitzgerald AL, Myers JN, Frederick MJ. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53. Mol Cancer Ther. .12(9):1860-73, 2013. PMCID: PMC3955083
View in: PubMed

3.Yang CZ, Ma J, Luo QQ, Neskey DM, Zhu DW, Liu Y, Myers JN, Zhang CP, Zhang ZY, Zhong LP. Elevated level of serum growth differentiation factor 15 is associated with oral leukoplakia and oral squamous cell carcinoma. J Oral Pathol Med. .43(1):28-34, 2013.
View in: PubMed

4.Pickering CR, Zhang J, Yoo SY, Bengtsson L, Moorthy S, Neskey DM, Zhao M, Ortega Alves MV, Chang K, Drummond J, Cortez E, Xie TX, Zhang D, Chung W, Issa JP, Zweidler-McKay PA, Wu X, El-Naggar AK, Weinstein JN, Wang J, Muzny DM, Gibbs RA, Wheeler DA, Myers JN, Frederick MJ. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov. .3(7):770-81, 2013. PMCID: PMC3858325
View in: PubMed

5.Perez A, Neskey DM, Wen J, Pereira L, Reategui EP, Goodwin WJ, Carraway KL, Franzmann EJ. CD44 interacts with EGFR and promotes head and neck squamous cell carcinoma initiation and progression. Oral Oncol. .49(4):306-13, 2012. PMCID: PMC3594090
View in: PubMed

6.Eloy JA, Neskey DM, Vivero RJ, Ruiz JW, Choudhry OJ, Casiano RR. High-resolution computed tomography analysis of the frontal sinus ostium: a pilot study. Am J Otolaryngol. .34(2):99-102, 2012.
View in: PubMed

7.Ma J, Liu Y, Huang XL, Zhang ZY, Myers JN, Neskey DM, Zhong LP. Induction chemotherapy decreases the rate of distant metastasis in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional control: a meta-analysis. Oral Oncol. .48(11):1076-84, 2012.
View in: PubMed

8.Neskey DM, Hatoum G, Modh R, Civantos F, Telischi FF, Angeli SI, Weed D, Sargi Z. Outcomes after surgical resection of head and neck paragangliomas: a review of 61 patients. Skull Base. .21(3):171-6, 2011. PMCID: PMC3312103
View in: PubMed

9.Lee SL, Neskey D, Mouzakes J. Potential predisposition for nasal septal perforation with methotrexate use: report of 2 cases and literature review. Ear Nose Throat J. .88(8):E12-4, 2009.
View in: PubMed

10.Neskey DM, Ambesi A, Pumiglia KM, McKeown-Longo PJ. Endostatin and anastellin inhibit distinct aspects of the angiogenic process. J Exp Clin Cancer Res. .27:61, 2008. PMCID: PMC2584004
View in: PubMed

11.Gross KL, Neskey DM, Manchanda N, Weremowicz S, Kleinman MS, Nowak RA, Ligon AH, Rogalla P, Drechsler K, Bullerdiek J, Morton CC. HMGA2 expression in uterine leiomyomata and myometrium: quantitative analysis and tissue culture studies. Genes Chromosomes Cancer. .38(1):68-79, 2003.
View in: PubMed

12.Quade BJ, Weremowicz S, Neskey DM, Vanni R, Ladd C, Dal Cin P, Morton CC. Fusion transcripts involving HMGA2 are not a common molecular mechanism in uterine leiomyomata with rearrangements in 12q15. Cancer Res. .63(6):1351-8, 2003.
View in: PubMed

13.Dal Cin P, Quade BJ, Neskey DM, Kleinman MS, Weremowicz S, Morton CC. Intravenous leiomyomatosis is characterized by a der(14)t(12;14)(q15;q24). Genes Chromosomes Cancer. .36(2):205-6, 2003.
View in: PubMed

14.Quade BJ, Dal Cin P, Neskey DM, Weremowicz S, Morton CC. Intravenous leiomyomatosis: molecular and cytogenetic analysis of a case. Mod Pathol. .15(3):351-6, 2002.
View in: PubMed

15.Nucci MR, Weremowicz S, Neskey DM, Sornberger K, Tallini G, Morton CC, Quade BJ. Chromosomal translocation t(8;12) induces aberrant HMGIC expression in aggressive angiomyxoma of the vulva. Genes Chromosomes Cancer. .32(2):172-6, 2001.
View in: PubMed